Displaying 241 - 250 of 516
This position statement provides guidance on follow-on biologics versus biosimilars, interchangeability and substitution, FDA draft guidance for interchangeability of biosimilars, and clinical application.
Read Position Statement
moreThis consensus statement provides a practical approach to management of patients with newly diagnosed adrenocortical carcinoma, as well as follow-up and management of patients with persistent or recurrent disease, including the management of an adrenal mass, presurgical evaluation, surgical approach, pathologic assessment, and other therapeutic modalities, based on individual patient presentation.
Read Consensus Statement moreThis consensus statement provides a practical approach to the evaluation of incidentally discovered adrenal masses, presenting five patient case scenarios selected to highlight a unique and relatively characteristic presentation that clinicians may encounter and answering key questions to help guide evaluation, diagnosis, management, and treatment.
Read Consensus Statement moreThis statement addresses the use of somatostatin-receptor ligands (SRLs) as preoperative therapy for individuals with acromegaly to improve outcomes.
Read Consensus Statement moreThis consensus statement provides information on novel minimally invasive therapeutic interventions for thyroid malignancies such as percutaneous ethanol injection and thermal ablation. The statement summarizes existing knowledge and provides guidance on indications, techniques, complications, and follow-ups for care of patients with benign and malignant thyroid lesions.
Read Consensus Statement moreCo-sponsored by the American Head and Neck Society Endocrine Surgery Section (AHNS)
This consensus statement outlines expert opinion and practical information on the evaluation of thyroid nodules, surgical considerations, and postoperative monitoring for children and adolescents with benign and malignant thyroid lesions.
Read Consensus Statement more
Co-sponsored by the American Association for the Study of Liver Diseases (AASLD)
This guideline provides evidence-based recommendations regarding the diagnosis and management of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) to endocrinologists, primary care clinicians, health care professionals, and other stakeholders.
Read Guideline
AACE Podcasts Episode 31:
Listen to endocrine expert Vin Tangpricha, M.D., Ph.D., as he interviews AACE Co-…
more
TThis 2017 update in CPG development focused on updated ratings for evidence and grading of recommendations for a more transparent process. Coming soon--2023 update to the AACE Protocol for Guidance Document Development.
Read Protocol
moreAlgorithm
Obesity
In process
Clinical Practice Guideline (developed according to GRADE framework)
Dyslipidemia
Published February 2025
Consensus Statement
Multiple Endocrine Neoplasia Type 1
Accepted for publication April 2025
Algorithm
Dyslipidemia
In process
Algorithm
Type 2 Diabetes
In process
Guideline
Postmenopausal Osteoporosis
In process
Consensus Statement
Diabetes Technology
In process
moreOnly topics nominated by AACE members in good standing will be considered.
Topics are reviewed by the Clinical Practice Guidelines (CPG) Oversight Committee twice a year (approximately in March and September). Approval does not guarantee that a guidance document on the topic will be developed within a certain timeframe. AACE plans initiation of approved topics in the context of current and other approved documents in queue for development, dependent on budget and availability of personnel and resources.
AACE members who nominated approved topics may apply to be considered for selection…
more
